Multiple Sclerosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | BrainStorm Cell Therapeutics, TG Therapeutics (ublituximab), Immunic, ANOKION

 Breaking News
  • No posts were found

Multiple Sclerosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | BrainStorm Cell Therapeutics, TG Therapeutics (ublituximab), Immunic, ANOKION

September 26
20:08 2022
Multiple Sclerosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | BrainStorm Cell Therapeutics, TG Therapeutics (ublituximab), Immunic, ANOKION
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Multiple Sclerosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Multiple Sclerosis Pipeline Insight, 2022″ report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Multiple Sclerosis Market. 

The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Multiple Sclerosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Multiple Sclerosis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Multiple Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Key Developments in the Multiple Sclerosis Therapeutics Market

• On September 15, 2022, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced the peer-reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis (MS) in the Multiple Sclerosis Journal.

• On August 25, 2022, TG Therapeutics, Inc. (NASDAQ: TGTX) announced results from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, an investigational anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS).

As per DelveInsight, the Multiple Sclerosis market size shall increase in the coming years owing to the launch of upcoming therapies, increasing healthcare expenditure, a rise in R&D activities, and awareness among patients about the treatment options. 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Multiple Sclerosis Therapeutic Segment:

Multiple Sclerosis Therapeutics Landscape

There are approx. 100+ key companies which are developing therapies for Multiple sclerosis. Currently, TG Therapeutics has its Multiple sclerosis drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Multiple Sclerosis Therapeutics Market include:

TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, ASLAN Pharmaceuticals,  GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics,  Autobahn Therapeutics,  AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn,  Pear Therapeutics,  ABION, Genzyme, NervGen, Biogen Idec, Acorda Therapeutics, Adamas Pharmaceuticals, Bayer Healthcare, Celgene Corporation, Johnson & Johnson, MedDay Pharma, Teva Pharmaceutical, and many others.

Multiple sclerosis Emerging Drugs Covered in the report include:

• Ublituximab: TG Therapeutics

• IMU-838: Immunic

• ATA188: Atara Biotherapeutics


And many more 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Multiple Sclerosis Current Treatment Patterns

4. Multiple Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple Sclerosis Late Stage Products (Phase-III)

7. Multiple Sclerosis Mid-Stage Products (Phase-II)

8. Multiple Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple Sclerosis Discontinued Products

13. Multiple Sclerosis Product Profiles

14. Key Companies in the Multiple Sclerosis Market

15. Key Products in the Multiple Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Multiple Sclerosis Unmet Needs

18. Multiple Sclerosis Future Perspectives

19. Multiple Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Undifferentiated Pleomorphic Sarcoma Market

“Undifferentiated Pleomorphic Sarcoma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles